DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...

Geneos Wealth Management Inc. lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.6% in the ...

Exchange Traded Concepts LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 12.4% in the ...

Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation ...

(Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by ...

In a report released today, Jeff Johnson from Robert W. Baird upgraded Dexcom (DXCM – Research Report) to a Buy, with a price target of ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...

Strong Product Demand: We are upbeat about DexCom's continued strength in CGM products. DexCom demonstrated strong product demand in third-quarter 2024, highlighted by record new patient starts in ...

Oversold Healthcare Stocks to Buy The sale of CGM devices is the primary revenue generator for the company, along with software and other services. Its top products include the Dexcom G6 which ...